EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The use of atypical antipsychotic medications in the treatment of children and adolescents with avoidant/restrictive food intake disorder

Mariela Mosheva, Yaron Sela, Shani Arad-Rubinshtein, Yaffa Serur, Ganit Omer, Nimrod Hertz-Palmor, Doron Gothelf, Daniel Stein

European Child & Adolescent Psychiatry · 2025

DOI: 10.1007/s00787-025-02713-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Child & Adolescent Psychiatry, 2025. Verfasst von Mariela Mosheva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Child Psychiatry Division, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, 5262000, Israel. marymoshev@gmail.com. Hauptthemen laut MEDLINE: Antipsychotic Agents, Risperidone, Avoidant Restrictive Food Intake Disorder, Weight Gain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Avoidant restrictive food intake disorder (ARFID) is a childhood feeding and eating disorder often associated with marked physical and psychosocial impairment.

Objective

We assessed the use of atypical antipsychotic (AAP) medications (mostly risperidone) in promoting weight and height gain in children with ARFID.

Methods

The computerized medical records of 21 children with ARFID receiving AAPs in one center in Israel were retrospectively reviewed. Fourteen children received AAPs after 6.30 ± 0.75 months of no weight gain with treatment as usual (either group or individual cognitive behavioral therapy); seven children were admitted to our clinic receiving AAPs in previous facilities because of lack of weight gain. All were followed-up for 18 months. Weight and height were extracted from the medial records at eight time points.

Results

A significant increase was found in weight, height, and body mass index (BMI) over 18 months of treatment with AAPs (Δweight: 9.66 ± 9.24 kg, p < 0.001; Δheight: 10.23 ± 11.54 cm, p < 0.001; ΔBMI = 2.55 ± 1.53 kg/m 2 ; p < 0.001). Weight increased significantly for both sexes, while height increased significantly only for boys. Patients with both low and high baseline BMI percentiles gained weight, while mean height increased significantly over time only for children with low BMI percentile. The use of a retrospective clinical global impression scale indicated a marked improvement over time. Adverse effects were minimal, and no patients discontinued AAPs due to adverse events.

Conclusion

The addition of AAPs for a period of 18 months may be safe and effective in increasing weight and height in children with ARFID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsRisperidoneAvoidant Restrictive Food Intake DisorderWeight GainHumansMaleFemaleChildAdolescentRetrospective StudiesIsraelBody HeightBody Mass IndexBody WeightTreatment OutcomeCognitive Behavioral Therapy

Stichwörter der Autor:innen

ARFIDAtypical antipsychotic medicationsBody mass indexHeightWeight

Substanzen

Antipsychotic AgentsRisperidone

Autor:innen und Institutionen

  • Child Psychiatry Division, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, 5262000, Israel. marymoshev@gmail.com.
  • The Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. marymoshev@gmail.com.
  • The Research Center for Internet Psychology, Reichman University, Herzliya, Israel.
  • Child Psychiatry Division, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, 5262000, Israel.
  • The Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.

Förderung

  • Tel Aviv University

Zitieren

APA

Mosheva, M., Sela, Y., Arad-Rubinshtein, S., Serur, Y., Omer, G., Hertz-Palmor, N., Gothelf, D., & Stein, D. (2025). The use of atypical antipsychotic medications in the treatment of children and adolescents with avoidant/restrictive food intake disorder. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-025-02713-w

Vancouver

Mosheva M, Sela Y, Arad-Rubinshtein S, Serur Y, Omer G, Hertz-Palmor N, et al. The use of atypical antipsychotic medications in the treatment of children and adolescents with avoidant/restrictive food intake disorder. European Child & Adolescent Psychiatry. 2025. doi:10.1007/s00787-025-02713-w

BibTeX
@article{Mosheva2025,
  author = {Mosheva, Mariela and Sela, Yaron and Arad-Rubinshtein, Shani and Serur, Yaffa and Omer, Ganit and Hertz-Palmor, Nimrod and Gothelf, Doron and Stein, Daniel},
  title = {The use of atypical antipsychotic medications in the treatment of children and adolescents with avoidant/restrictive food intake disorder},
  journal = {European Child & Adolescent Psychiatry},
  year = {2025},
  doi = {10.1007/s00787-025-02713-w}
}
Kostenlos starten →